A Maryland-based Pharmaceutical Company Acquires Narcan Opioid Overdose Nasal Spray Manufacturer
The Baltimore Sun reports that Emergent Solutions has approved $ 735 million in cash and shares in Ireland-based Adapt Pharma to pay. CEO Daniel J. Abdun-Nabi said in a Wednesday statement that the widely used drug is consistent with Emergent's position to "protect and improve life".
The federal government has declared the opioid epidemic a public health emergency claiming thousands of lives. 19659002] Narcan is the only approved nasal spray version of Naxolon that costs $ 150 for two cans. While public health programs can negotiate lower prices, access and affordability remain a problem.
Doug White of Emergent says the company plans to invest in addiction and overdose drugs and work with federal officials to ensure grants to offset costs